Di Virgilio F. Purines, purinergic receptors, and cancer. Cancer Res —7. Role of adenosine signaling in the pathogenesis of breast cancer. J Cell Physiol — Basic Clin Pharmacol Toxicol — Reduced adenosine-to-inosine miRp editing promotes melanoma growth and metastasis. Nat Cell Biol — Adenosine-to-inosine RNA editing meets cancer.
Carcinogenesis — Purine nucleosides downregulate innate immune function and arrest apoptosis in teleost fish leucocytes. J Immunol Google Scholar. Idzko M. Purines in tissue inflammation and fibrosis.
Purinergic Signal Glioblastoma cancer stem cells evade innate immune suppression of self-renewal through reduced TLR4 expression. Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol — Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma?
Ann Oncol —2. Impact of selenium supplementation in neutropenia and immunoglobulin production in childhood cancer patients. J Med Food —8. Burnstock G, Boeynaems JM. Purinergic signalling and immune cells. Purinergic Signal — Adenosine deaminase in saliva as a diagnostic marker of squamous cell carcinoma of tongue. Clin Oral Investig —9.
Diagnostic significance of adenosine deaminase, uric acid and C-reactive protein levels in patients of head and neck carcinoma. Clin Lab —8. PubMed Abstract Google Scholar. Immunity, inflammation and cancer: a leading role for adenosine. Kumar V. Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Immunoregulatory activity of adenosine and its role in human cancer progression. Expert Rev Clin Immunol — Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer.
Mol Carcinog E32— Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest — Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science —4. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature — Serine and glycine metabolism in cancer. Trends Biochem Sci —8. Yang M, Vousden KH. Serine and one-carbon metabolism in cancer. SLC25A22 promotes proliferation and survival of colorectal cancer cells with KRAS mutations and xenograft tumor progression in mice via intracellular synthesis of aspartate.
Gastroenterology — Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab — Oncogene —8. One-carbon metabolism in cancer. Br J Cancer — Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature —6. Serine starvation induces stress and pdependent metabolic remodelling in cancer cells.
Gene set analysis of purine and pyrimidine antimetabolites cancer therapies. Pharmacogenet Genomics — Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev — Peters GJ. Novel developments in the use of antimetabolites. Nucleosides Nucleotides Nucleic Acids — Tiwari M. Antimetabolites: established cancer therapy. J Cancer Res Ther —9. Activity and mechanism of action of 6-methylthiopurine ribonucleoside in cancer cells resistant to 6-mercaptopurine.
Nature Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors. Ann Oncol —7. Activation of xanthine oxidase suppresses disulfide bond formation of breast cancer resistance protein in Caco-2 cells. Drug Metab Rev Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen.
Biochem Pharmacol — J Clin Biochem Nutr —9. Membrane cholesterol access into a G-protein-coupled receptor. Nat Commun 8. Gastroenterology S82—3. Cell-surface G-protein-coupled receptors for tumor-associated metabolites: a direct link to mitochondrial dysfunction in cancer.
GPCRs regulate the assembly of a multienzyme complex for purine biosynthesis. Nat Chem Biol — G-protein-coupled receptor regulation of de novo purine biosynthesis: a novel druggable mechanism.
Biotechnol Genet Eng Rev — Role of HSP90 in the regulation of de novo purine biosynthesis. Methotrexate induced differentiation in colon cancer cells is primarily due to purine deprivation. J Cell Biochem — Methotrexate chemotherapy in elderly patients with locally advanced head and neck cancer: preliminary results. Ann Oncol The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition. Cancer Lett — Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer.
Nat Commun 5. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci — Cell Rep — Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science —5. From Krebs to clinic: glutamine metabolism to cancer therapy. The mechanism of differential effect of metformin on colorectal cancer cells: metabolic alteration via glutamine pathway. Gastroenterology S— U ridinephosphate constitutes the building block of the subsequent reactions.
On the other hand, uridinephosphate can be reduced to d-UMP by the action of d-TMP-synthetase thymidylate-synthase. The methyl group that is required for this conversion is obtained from N 5 , N 10 -methylene tetrahydro folate , which in turn is converted to dihydrof olate.
Ribonucleotide reductase catalyzes this reaction in the presence of thioredoxin as a cofactor. Thioredoxin, in turn, contains two SH groups , which are converted to the disulfide form after reduction. Similar to the stepwise synthesis of purine nucleotides, their degradation also occurs via multiple steps. The steps involved in degradation depends on the purine bases adenosine or guanosine that are present. The first step in the degradation reaction is the conversion of the nucleotide to the nucleoside.
This occurs through a hydrolysis reaction mediated by nucleotidase. Additionally, a phosphate molecule is lost, which leads to the formation of a free base purine or pyrimidine and ribosephosphate. This step is mediated by nucleoside phosphorylase. The degradation of the purine bases, adenosine and guanosine, occurs subsequently. First, adenosine undergoes deamination in the presence of adenosine deaminase and is converted to inosine. The second step is identical for both inosine and guanosine, in which they are converted to hypoxanthine and guanine, respectively, through an ATP-dependent removal of ribose.
Similar to the previous step, this reaction is mediated by nucleoside phosphorylase. In the next step, inosine and hypoxanthine are converted to xanthine. However, this step proceeds differently for each nucleoside. Guanine is deaminated to xanthine, whereas hypoxanthine is oxidized to xanthine in the presence of xanthine oxidase.
Note : Xanthine oxidase is an iron-bearing flavoprotein that contains a molybdenum atom in its active center. Another reaction mediated by xanthine oxidase is the conversion of xanthine to uric acid.
This step also proceeds via oxidation, where molecular oxygen serves as a means for oxidation. Eventually, the uric acid that is generated is excreted in the urine. When this level is exceeded, urate crystals are formed, which accumulate in tissues and joints leading to local inflammation or gout. Poor vascularization and low temperatures promote the crystallization of uric acid, which likely explains why the metatarsophalangeal joint podagra , cornea, and the lens of the eye are potential sites for uric-acid deposition.
Gout-affected joints appear flushed, overheated, and swollen, and are very painful. These presentations represent the cardinal signs of inflammation rubor, calor, tumor, and dolor.
Enzyme defects can also lead to increased or diminished uric acid levels. A partial or complete lack of hypoxanthine-guanine phosphoribosyltransferase results in increased uric acid levels.
A deficiency of this enzyme results in a condition known as Kelley-Seegmiller syndrome , which is associated with high purine levels. Lesch-Nyhan syndrome is a condition resulting from the complete lack of hypoxanthine-guanine phosphoribosyltransferase. The affected children present a trio of hyperuricemia, progressive kidney insufficiency, and neurological symptoms, for example, a tendency to self-mutilate. Conversely, reduced xanthine oxidase activity can lead to diminished uric acid levels and the accumulation of xanthine xanthinuria.
Note : Xanthine oxidase activity can be inhibited using allopurinol during the management of gout. Some other factors influencing uric acid levels include renal function uric acid secretion , an increased cell turnover diseases including leukemia , or high-purine foods beer, fish, and certain meats. The first step in the degradation of pyrimidine nucleotides is their conversion to nucleosides, similar to that discussed in the degradation of purine nucleotides.
The degradation of cytosine and thymine, produced in the first step of the degradation of pyrimidine bases, occurs in the liver. Note : The pyrimidine ring is broken down during nucleotide degradation; however, the purine ring is preserved during the degradation process. Cytosine and thymine undergo independent degradation pathways in which the reaction steps are identical except for the first step in the degradation of cytosine.
In this first step, cytosine is degraded to uracil by the removal of an amino group. The nitrogen atoms resulting from the breakdown are utilized in the urea cycle. The degradation of purine nucleotides does not result in any energy gain, whereas the breakdown of pyrimidine nucleotides results in only marginal energy generation. Since the synthesis of both purine and pyrimidine nucleotides requires significant energy, recycling is an energetically viable option. This occurs via the salvage pathway.
The exact steps involved in recycling are only known for purine bases and are discussed below. First, the purine bases are phosphoribosylized to nucleotides by PRPP. The transmission of each purine base to PRPP in adenine is mediated by adenine phosphoribosyltransferase, while hypoxanthine-guanine phosphoribosyltransferase catalyzes this reaction for hypoxanthine and guanine.
Comment on its solubility and indicate its role in gout, Lesch-Nyhan syndrome, and von Gierke disease. Identify reactions whose impairment leads to modified pathologic signs and symptoms. Indicate why there are few clinically significant disorders of pyrimidine catabolism.
Despite a diet that may be rich in nucleoproteins, dietary purines and pyrimidines are not incorporated directly into tissue nucleic acids.
However, injected purine or pyrimidine analogs, including potential anticancer drugs, may nevertheless be incorporated into DNA. Coordinated feedback mechanisms ensure their production in appropriate quantities and at times that match varying physiologic demand eg, cell division. Human diseases that involve abnormalities in purine metabolism include gout, Lesch-Nyhan syndrome, adenosine deaminase deficiency, and purine nucleoside phosphorylase deficiency.
Diseases of pyrimidine biosynthesis are rarer, but include orotic acidurias. A nongenetic form can be triggered by administration of 5-fluorouracil to patients with low levels of dihydropyrimidine dehydrogenase.
Normal human tissues can synthesize purines and pyrimidines from amphibolic intermediates in quantities and at times appropriate to meet variable physiologic demand.
Ingested nucleic acids and nucleotides therefore are dietarily nonessential. Following their degradation in the intestinal tract, the resulting mononucleotides may be absorbed or converted to purine and pyrimidine bases. The purine bases are then oxidized to uric acid, which may be absorbed and excreted in the urine. While little or no dietary purine or pyrimidine is incorporated Your MyAccess profile is currently affiliated with '[InstitutionA]' and is in the process of switching affiliations to '[InstitutionB]'.
This div only appears when the trigger link is hovered over. Otherwise it is hidden from view. Forgot Username? About MyAccess If your institution subscribes to this resource, and you don't have a MyAccess Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Learn More.
0コメント